Next Article in Journal
A Low-Cost Inkjet-Printed Aptamer-Based Electrochemical Biosensor for the Selective Detection of Lysozyme
Next Article in Special Issue
Fabrication of SrTiO3 Layer on Pt Electrode for Label-Free Capacitive Biosensors
Previous Article in Journal
Acknowledgement to Reviewers of Biosensors in 2017
Previous Article in Special Issue
Label-Free Biosensor Detection of Endocrine Disrupting Compounds Using Engineered Estrogen Receptors
Open AccessFeature PaperArticle

Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening

1
Integrated Systems Laboratory (LSI), Swiss Federal Institute of Technology Lausanne, EPFL, CH-1015 Lausanne, Switzerland
2
Bionanophotonic Systems Laboratory (BIOS), Swiss Federal Institute of Technology Lausanne, EPFL, CH-1015 Lausanne, Switzerland
3
Department of Chemistry, Sharif University of Technology, Tehran 11155-9516, Iran
*
Author to whom correspondence should be addressed.
The authors contribute equally to this work.
Biosensors 2018, 8(1), 6; https://doi.org/10.3390/bios8010006
Received: 30 November 2017 / Revised: 22 December 2017 / Accepted: 8 January 2018 / Published: 9 January 2018
(This article belongs to the Special Issue Label-free Biosensing)
The pharmaceutical industry is facing enormous challenges due to high drug attribution rates. For the past decades, novel methods have been developed for safety and efficacy testing, as well as for improving early development stages. In vitro screening methods for drug-receptor binding are considered to be good alternatives for decreasing costs in the identification of drug candidates. However, these methods require lengthy and troublesome labeling steps. Biosensors hold great promise due to the fact that label-free detection schemes can be designed in an easy and low-cost manner. In this paper, for the first time in the literature, we aimed to compare the potential of label-free optical and impedimetric electrochemical biosensors for the screening of antipsychotic drugs (APDs) based on their binding properties to dopamine receptors. Particularly, we have chosen a currently-used atypical antipsychotic drug (Buspirone) for investigating its dopamine D3 receptor (D3R) binding properties using an impedimetric biosensor and a nanoplasmonic biosensor. Both biosensors have been specifically functionalized and characterized for achieving a highly-sensitive and reliable analysis of drug-D3R binding. Our biosensor strategies allow for comparing different affinities against the D3R, which facilitates the identification of strong or weak dopamine antagonists via in vitro assays. This work demonstrates the unique potential of label-free biosensors for the implementation of cost-efficient and simpler analytical tools for the screening of antipsychotic drugs. View Full-Text
Keywords: label-free detection; drug screening; dopamine receptor; electrochemical biosensor; nanoplasmonic biosensor label-free detection; drug screening; dopamine receptor; electrochemical biosensor; nanoplasmonic biosensor
Show Figures

Figure 1

MDPI and ACS Style

Kilic, T.; Soler, M.; Fahimi-Kashani, N.; Altug, H.; Carrara, S. Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening. Biosensors 2018, 8, 6.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop